August 2022 RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. , dear Colleagues, It gives me great pleasure to announce the fourth hybrid symposium on regulatory autoantibodies Recently, functional autoantibodies targeting GPCRs have been associated with various disease-specific Therefore, the aim of this symposium is to bring together the current knowledge on the role of autoantibodies In addition, one aim is to bring together the mode of action of autoantibodies in immune regulation and

Regulatory autoantibodies (abs) are discussed, which are parts of the human physiology and are specifically

October 2022 Structural perspectives on the mechanism of signal activation, ligand selectivity and allosteric modulation in angiotensin receptors: IUPHAR Review 34 "Functional advances have guided our knowledge of physiological and fatal pathological mechanisms of the hormone angiotensin II (AngII) and its antagonists. Such studies revealed that tissue response to a given dose of the hormone or its antagonist depends on receptors that engage the ligand. Thus, we need to know much more about the structures of receptor-ligand complexes at high resolution. Recently, X-ray structures of both AngII receptors (AT1 and AT2 receptors) bound to peptide and non-peptide ligands have been elucidated, providing new opportunities to examine the dynamic fluxes in the 3D architecture of the receptors, as the basis of ligand selectivity, efficacy, and regulation of the molecular functions of the receptors. Constituent structural motifs cooperatively transform ligand selectivity into specific functions, thus conceptualizing the primacy of the 3D structure over individual motifs of receptors. This review covers the new data elucidating the structural dynamics of AngII receptors and how structural knowledge can be transformative in understanding the mechanisms underlying the physiology of AngII." Read more at the source #DrGPCR #GPCR #IndustryNews

or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies Acquired hypocalciuric hypercalcemia (AHH) is a rare disease caused by calcium-sensing receptor (CaSR) autoantibodies exacerbations could be successfully treated with prednisolone and/or calcimimetics, (f) the presence of CaSR autoantibodies

of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated ß2-Adrenergic Receptor Autoantibodies-An

GPCR Binders, Drugs, and more Autoantibodies targeting G protein-coupled receptors: An evolving history

in Cancer Cell Lines Severity of neurological long-COVID symptoms correlates with increased level of autoantibodies

and Pharmacological Perspectives COVID-19, G protein-coupled receptor, and renin-angiotensin system autoantibodies

Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19.

GPCRs in Oncology and Immunology Receptor autoantibodies: Associations with cardiac markers, histology

GPCRs in Cardiology, Endocrinology, and Taste Receptor autoantibodies: Associations with cardiac markers